Peter Bressler, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1932133329
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,128 of the $7,824 with a category attached, or 65.5%. 44 manufacturers reported payments, led by Eli Lilly at 29.3% of the total. Reporting peaked in 2022 at $2,756 and has fallen 65.4% since, to $953 in 2025.
Across 258 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Sanofi-aventis U.S. LLC$761
- Tandem Diabetes Care, Inc.$544
- Novo Nordisk$498
- Lilly USA, LLC$319
- Amgen$270
- plus $3K from 38 others
Across 1,871 payments — averaging $2260.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.3M
- Novo Nordisk AS$555K
- AbbVie$544K
- Astrazeneca UK Limited$347K
- Novartis$255K
- Kowa Research Institute, Inc.$91K
- plus $147K from 7 others
What the payments were for
- Speaking & faculty fees$6508%
- Travel & lodging$2,00226%
- Food & beverage$5,12866%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,824 in reported general payments places this provider in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $226,485 |
| JardianceEmpagliflozin | 146 | $194,887 |
| MounjaroTirzepatide | 131 | $168,874 |
| TrulicityDulaglutide | 81 | $125,510 |
| Teriparatide | 43 | $106,056 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $88,829 |
| FarxigaDapagliflozin Propanediol | 50 | $64,395 |
| TymlosAbaloparatide | 21 | $58,107 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $45,289 |
| JanuviaSitagliptin Phosphate | 42 | $38,486 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $38,030 |
| SynthroidLevothyroxine Sodium | 331 | $37,311 |
| TradjentaLinagliptin | 40 | $28,838 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $25,903 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 13 | $23,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $319 | $309,740255 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $498 | $271,262215 claims |
| Boehringer IngelheimJardiance, Tradjenta | $152 | $223,725186 claims |
| Alvogen IncTeriparatide | $42 | $106,05643 claims |
| AstraZenecaFarxiga | $108 | $64,39550 claims |
| Radius Health, Inc.Tymlos | $143 | $58,10721 claims |
| MerckJanuvia, Janumet Xr | $12 | $51,75757 claims |
| AbbVieSynthroid | $95 | $37,311331 claims |
| Cequr CorporationCequr Simplicity | $174 | $11,55024 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $105 | $9,628587 claims |
| Sanofi-aventis U.S. LLCLantus | $761 | $3,29730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.